- Home
- UGRO vs SNGX Comparison
UGRO vs SNGX Comparison
Compare UGRO & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- SNGX
- Stock Information
- Founded
- UGRO 2014
- SNGX 1987
- Country
- UGRO United States
- SNGX United States
- Employees
- UGRO N/A
- SNGX N/A
- Industry
- UGRO Industrial Specialties
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- SNGX Health Care
- Exchange
- UGRO Nasdaq
- SNGX Nasdaq
- Market Cap
- UGRO 8.8M
- SNGX 7.4M
- IPO Year
- UGRO N/A
- SNGX 1987
- Fundamental
- Price
- UGRO $0.77
- SNGX $2.34
- Analyst Decision
- UGRO Strong Buy
- SNGX
- Analyst Count
- UGRO 2
- SNGX 0
- Target Price
- UGRO $5.63
- SNGX N/A
- AVG Volume (30 Days)
- UGRO 131.9K
- SNGX 620.7K
- Earning Date
- UGRO 03-26-2025
- SNGX 03-14-2025
- Dividend Yield
- UGRO N/A
- SNGX N/A
- EPS Growth
- UGRO N/A
- SNGX N/A
- EPS
- UGRO N/A
- SNGX N/A
- Revenue
- UGRO $70,320,066.00
- SNGX $364,183.00
- Revenue This Year
- UGRO $17.15
- SNGX N/A
- Revenue Next Year
- UGRO $21.76
- SNGX $76.64
- P/E Ratio
- UGRO N/A
- SNGX N/A
- Revenue Growth
- UGRO 12.08
- SNGX N/A
- 52 Week Low
- UGRO $0.60
- SNGX $1.83
- 52 Week High
- UGRO $2.84
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- UGRO 38.00
- SNGX 36.12
- Support Level
- UGRO $0.70
- SNGX $2.23
- Resistance Level
- UGRO $1.12
- SNGX $2.39
- Average True Range (ATR)
- UGRO 0.12
- SNGX 0.17
- MACD
- UGRO 0.01
- SNGX 0.01
- Stochastic Oscillator
- UGRO 32.56
- SNGX 22.12
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).